(lp0
S"Here's Why Ligand Pharmaceuticals Inc Is Plunging Today Motley Fool - Sep 27, 2016 Shares of Ligand Pharmaceuticals , an owner of royalty assets in the healthcare space, are falling by more than 13% as of 3:30 p.m.Amgen's Multiple Myeloma Drug Bumbles Key Test Vs. Blockbuster Velcade - Investor's Business Daily"
p1
aS'Licensing Agreements Drive Ligand Pharmaceuticals Inc. 13% Higher in July Motley Fool - Aug 8, 2016 What: Shares of Ligand Pharmaceuticals , an acquirer of royalty assets in the biotech space, surged 13% in July, according to data from S&amp;P Global Market Intelligence.'
p2
aS'Lawsuit for Investors in Ligand Pharmaceuticals Inc.  over ... GlobeNewswire  - Nov 29, 2016 SAN DIEGO, Nov. 29, 2016  -- The Shareholders Foundation, Inc. announces that a lawsuit was filed in California on behalf of certain purchasers of shares of Ligand Pharmaceuticals Inc.  over alleged Securities Laws&nbsp;...'
p3
aS'Ligand Pharmaceuticals Inc. Investigated For Securities Fraud By Block ... PR Newswire  - Nov 16, 2016 BOSTON, Nov. 15, 2016 /PRNewswire/ -- Block &amp; Leviton LLP , a securities litigation firm representing investors nationwide, is investigating whether Ligand Pharmaceuticals Inc.  and certain of its officers and directors&nbsp;...'
p4
aS"Analyst Update: Alphabet Inc, Facebook Inc, and Ligand Pharmaceuticals Inc. Schaeffers Research  - Sep 27, 2016 Analysts are weighing in on internet issue Alphabet Inc , social media stock Facebook Inc , and drugmaker Ligand Pharmaceuticals Inc. . Here's a quick roundup of today's brokerage notes on GOOGL, FB,&nbsp;..."
p5
aS'Zacks: Analysts Expect Ligand Pharmaceuticals Inc.  to Post $0.65 ... BNB Daily  - Apr 17, 2017 Ligand Pharmaceuticals logo Equities analysts expect that Ligand Pharmaceuticals Inc.  will report earnings of $0.65 per share for the current quarter, Zacks Investment Research reports.Ligand Pharmaceuticals Inc.  Expected to Post Quarterly Sales of $32.86 ... - Sports PerspectivesStock Returns: Halozyme Therapeutics Inc  is Beating Ligand ... - CML News'
p6
aS'Ligand Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for LGND Nasdaq - Mar 10, 2017 In trading on Friday, shares of Ligand Pharmaceuticals Inc  crossed above their 200 day moving average of $109.46, changing hands as high as $109.59 per share.'
p7
aS"Understanding Ligand Pharmaceuticals's PE Multiple Market Realist - Jul 14, 2016 If you are a risk-averse investor and still want to enjoy exposure to a growth-stage biopharmaceutical company such as Ligand Pharmaceuticals, you can invest in ETFs. The PowerShares Dynamic Pharmaceuticals Portfolio ETF  holds ~4.0% weight in&nbsp;..."
p8
aS"Ligand Pharmaceuticals'  CEO John Higgins on Q3 2016 Results - Earnings ... Seeking Alpha - Nov 4, 2016 The information on this conference call related to projections or other forward-looking represent the Company's best judgment based on information available and reviewed by the Company as of today, November 3, 2016 and do not necessarily represent the&nbsp;..."
p9
aS'Guggenheim Capital LLC Decreases Position in Ligand Pharmaceuticals Inc.  The Cerbat Gem - Apr 12, 2017 Ligand Pharmaceuticals logo Guggenheim Capital LLC cut its position in Ligand Pharmaceuticals Inc.  by 41.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission .Ligand Pharmaceuticals Inc.  Receives $135.18 Average Price Target from ... - Chaffey BreezeLigand Pharmaceuticals Inc.  Short Interest Down 1.0% in March - Markets Daily'
p10
a.